Importantly, cells from patients with ASXL1-mutated CLL were also sensitive to PARPi treatment that was otherwise ineffective on non–ASXL1 (TP53)-mutated CLL cells (Figure 6H). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.